Rothschild Investment Corp IL cut its position in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) by 55.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,990 shares of the biopharmaceutical company’s stock after selling 2,500 shares during the period. Rothschild Investment Corp IL’s holdings in Intercept Pharmaceuticals were worth $251,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. State of Wisconsin Investment Board boosted its position in shares of Intercept Pharmaceuticals by 95.9% during the second quarter. State of Wisconsin Investment Board now owns 22,700 shares of the biopharmaceutical company’s stock worth $1,905,000 after acquiring an additional 11,111 shares during the last quarter. FMR LLC boosted its position in shares of Intercept Pharmaceuticals by 17.5% during the second quarter. FMR LLC now owns 4,437,332 shares of the biopharmaceutical company’s stock worth $372,336,000 after acquiring an additional 661,542 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of Intercept Pharmaceuticals by 104.3% during the second quarter. Schwab Charles Investment Management Inc. now owns 110,805 shares of the biopharmaceutical company’s stock worth $9,298,000 after acquiring an additional 56,556 shares during the last quarter. Asymmetry Capital Management L.P. bought a new position in shares of Intercept Pharmaceuticals during the second quarter worth $2,175,000. Finally, Rhumbline Advisers boosted its position in shares of Intercept Pharmaceuticals by 11.5% during the second quarter. Rhumbline Advisers now owns 21,153 shares of the biopharmaceutical company’s stock worth $1,775,000 after acquiring an additional 2,181 shares during the last quarter. 69.38% of the stock is owned by hedge funds and other institutional investors.

In other Intercept Pharmaceuticals news, insider David Shapiro sold 759 shares of the stock in a transaction on Friday, October 5th. The shares were sold at an average price of $110.65, for a total transaction of $83,983.35. Following the completion of the transaction, the insider now owns 39,152 shares in the company, valued at $4,332,168.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 9,101 shares of company stock valued at $984,488 in the last quarter. 4.90% of the stock is owned by company insiders.

ICPT stock opened at $99.45 on Friday. Intercept Pharmaceuticals Inc has a 52 week low of $51.05 and a 52 week high of $133.74. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 2.48.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($2.58) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($2.83) by $0.25. Intercept Pharmaceuticals had a negative net margin of 215.30% and a negative return on equity of 614.15%. The business had revenue of $43.58 million during the quarter, compared to analyst estimates of $41.26 million. During the same quarter last year, the business earned ($3.46) earnings per share. Intercept Pharmaceuticals’s quarterly revenue was up 41.1% compared to the same quarter last year. Analysts forecast that Intercept Pharmaceuticals Inc will post -10.56 EPS for the current year.

A number of brokerages recently weighed in on ICPT. ValuEngine upgraded shares of Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, July 2nd. Raymond James began coverage on shares of Intercept Pharmaceuticals in a research report on Thursday, June 28th. They set a “strong-buy” rating and a $122.00 target price for the company. BidaskClub lowered shares of Intercept Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 11th. Oppenheimer set a $100.00 target price on shares of Intercept Pharmaceuticals and gave the stock a “hold” rating in a research report on Tuesday, July 17th. Finally, Royal Bank of Canada restated a “buy” rating and set a $115.00 target price on shares of Intercept Pharmaceuticals in a research report on Friday, August 3rd. Eight investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $139.88.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).

See Also: Retained Earnings

Want to see what other hedge funds are holding ICPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intercept Pharmaceuticals Inc (NASDAQ:ICPT).

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.